Collaborative Business Models: The Case of Big Pharmaceutical and Small Diagnostic Firms
Strategic Management Special Conference “Startup and Restart Strategies,” March 2014
Posted: 3 Aug 2014
Date Written: March 9, 2014
Abstract
Research and business developments often change the dynamics of an industry and require new forms of collaborative business models. Our paper discusses this phenomenon for an industry that has traditionally preferred to collaborate only for research purposes. Due to the rise of tandems, i.e., combination of drug and companion diagnostics, pharmaceutical and diagnostic firms have to change their traditional business models. Instead of delivering value to the customers on their own, companies depend heavily on each other. We find that firms choose either a collaborative or an individual approach for collaborative business model development. Hence, our research contributes to the discussion on forms of collaboration between big multinational pharmaceutical firms and small and medium-sized diagnostic firms.
Keywords: collaborative business model, companion diagnostic, inter-organizational business model, networked business model, personalized medicine, pharmaceutical industry, stratified drugs
Suggested Citation: Suggested Citation